Symbiotec Pharmalab logo

Symbiotec Pharmalab

Closes on 27 Aug
₹14,070/ 15 shares

Minimum investment

Minimum investment

₹14,070

Price range

₹938 - ₹988

Lot size

15

Issue size

₹1,757 Cr

IPO document

RHP PDF

Employee

₹12,720

HNI

₹1,96,980

Retail application

₹14,070

Qualified Institutional Buyers—
Non-Institutional Investor—
Retail Individual Investor—
Employees—
Total82.94x
✓

IPO open date

24 Aug

✓

IPO close date

27 Aug

✓

Allotment date

31 Aug

✓

Funds unblock or debit

31 Aug

✓

Tentative listing date

01 Sept

RegistrarMUFG Intime India Private Limited

Symbiotec Pharmalab is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. Its operations span three platforms — organic chemistry, biotechnology, and complex injectables. The company has a portfolio of over 60 corticosteroid and steroid hormone APIs, including hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies. As of March 31, 2026, the company had two operational API manufacturing facilities at Rau and Pithampur in Madhya Pradesh. It has also commissioned a biomanufacturing facility at Ujjain and a complex injectables facility at Mhow, Madhya Pradesh. The company operates three R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. Its products and services have been supplied to over 200 customers across more than 40 countries. Use of proceeds: The IPO consists of both a fresh issue and an offer for sale.​ Proceeds from the offer for sale segment will be directed to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes:​Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company — Rs 112.5 crore General corporate purposes

All values are in ₹ Cr

716

FY24

752

FY25

869

FY26

  • The company had a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs in FY26, excluding androstenedione and hydroxyprogesterone caproate. It also had market shares of 80.1%, 76.4%, and 76.0% by volume in hydrocortisone, testosterone, and methylprednisolone, respectively, in FY26.
  • The company has a portfolio of over 60 corticosteroid and steroidal-hormone APIs across sterile and non-sterile formats. As of March 31, 2026, its portfolio covered approximately 90% of corticosteroid and steroidal-hormone API products, and it had 43 drug master files registered with the US FDA and 23 certificates of suitability from the EDQM.
  • The company has a presence across domestic and international markets, with revenue from customers outside India at Rs 582.64 crore, Rs 414.47 crore, and Rs 429.62 crore in FY26, FY25, and FY24, respectively, accounting for 67.04%, 55.19%, and 59.97% of its revenue from operations. As of March 31, 2026, it served over 200 customers across more than 40 countries, including over 50 domestic customers and over 150 export customers.
  • The company claims to have a vertically integrated and multi-scale manufacturing platform. As of March 31, 2026, its facilities had an aggregate maximum chemical synthesis capacity of 584.67 MT, a fermentation capacity of 700 KL, and a complex injectable capacity of 20 million vials. It also claims that its backward integration allows it to make key starting materials for products representing over 80% of its revenue, reducing its dependence on externally sourced intermediates.
  • The company’s Rau and Pithampur facilities have approvals from regulatory authorities including the US FDA, EU-GMP, and WHO-GMP.
  • The company claims to have R&D capabilities across organic chemistry, biotechnology, and complex injectables and operated three dedicated R&D centres in Indore as of March 31, 2026. Its R&D expenditure stood at Rs 29.69 crore, Rs 31.14 crore, and Rs 20.51 crore in FY26, FY25, and FY24, respectively, accounting for 3.42%, 4.14%, and 2.86% of its revenue from operations, respectively.
  • The company has seen an increase in revenue from operations, which stood at Rs 716.25 crore, Rs 751.55 crore, and Rs 869.15 crore in FY24, FY25, and FY26, respectively.

FAQs

What is the issue size of Symbiotec Pharmalab IPO?

The issue size is ₹1,757 Cr.

What is the price band of Symbiotec Pharmalab IPO?

The price band is ₹938 to ₹988 per share.

What is the GMP of Symbiotec Pharmalab today?

The latest GMP is ₹270.

What is the subscription status of Symbiotec Pharmalab?

The latest available subscription figures are Overall 82.94x.

What are the open and close dates of Symbiotec Pharmalab IPO?

The IPO opens on 24 Aug 2026 and closes on 27 Aug 2026.

What is the allotment chance of Symbiotec Pharmalab IPO?

Allotment chance is not available because retail subscription data is not available.

What is the lot size of Symbiotec Pharmalab IPO?

The lot size is 15 shares.

Who is the registrar of Symbiotec Pharmalab IPO?

MUFG Intime India Private Limited

GMP Today

•

Est. premium

₹270

27.3%

Allotment Chance

i

—

Based on retail subscription